Allergan Aesthetics has secured FDA approval for Skinvive by Juvéderm for improvement of neck appearance—a first-to-market indication for a hyaluronic acid filler in this zone. The product uses Juvéderm's proprietary crosslinking technology and is positioned as a smooth-gel formulation designed for the thinner, more mobile skin of the neck and décolletage.
This approval matters because neck rejuvenation has historically relied on off-label filler use, laser, or RF microneedling. A cleared, labeled indication removes prescriber hesitation and creates a new revenue stream with minimal market education—most practices already stock Juvéderm. The neck is a high-visibility zone with strong patient demand and minimal competitive pressure from other fillers in this specific indication.